News
ARCT
9.84
-8.29%
-0.89
Weekly Report: what happened at ARCT last week (1012-1016)?
Weekly Report · 5d ago
Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call
Benzinga · 10/14 10:10
Vertex Pharmaceuticals Inc. Stock Sheds 4.3%, Underperforms Peers
Dow Jones · 10/13 20:34
Weekly Report: what happened at ARCT last week (1005-1009)?
Weekly Report · 10/12 10:18
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
Benzinga · 10/09 14:51
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 10/09 13:11
Arcturus Therapeutics (ARCT) Receives a Buy from Leerink Partners
TipRanks · 10/09 13:05
Arcturus Therapeutics Is Maintained at Outperform by Leerink Partners
Dow Jones · 10/09 12:38
Arcturus Therapeutics Price Target Raised to $19.00/Share From $13.00 by Leerink Partners
Dow Jones · 10/09 12:38
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Benzinga · 10/09 12:27
Novavax, Moderna cool as WHO downplays plague-related death in Russia
Seeking Alpha · 10/06 11:04
Wells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
TipRanks · 10/05 11:56
Weekly Report: what happened at ARCT last week (0928-1002)?
Weekly Report · 10/05 10:18
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Arcturus Therapeutics (ARCT)
TipRanks · 10/02 10:20
Arcutis Partners With Simone Biles To Raise Awareness Of Skin Conditions
NASDAQ · 09/29 14:41
Weekly Report: what happened at ARCT last week (0921-0925)?
Weekly Report · 09/28 10:13
Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts
TipRanks · 09/26 09:01
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Benzinga · 09/24 18:26
Arcturus Therapeutics Price Target Raised to $20.00/Share From $8.00 by Citigroup
Dow Jones · 09/24 15:56
Arcturus Therapeutics Raised to Buy From Neutral by Citigroup
Dow Jones · 09/24 15:56
More
Webull provides a variety of real-time ARCT stock news. You can receive the latest news about Arcturus Therape through multiple platforms. This information may help you make smarter investment decisions.
About ARCT
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.